secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001558370-23-014412
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx Q2 net loss $29.6M; Phase 3 XLRP trial enrollment surpassed; secures $25M note amendment
--------------------------------------------------------------------------------

- Q2 2023 net loss $29.6M ($0.53/share) vs $34.0M ($0.76) YoY; license revenue $3.5M (down from $10.8M).
- Cash $92.8M at June 30, 2023; with Janssen receivables, runway into Q2 2025.
- Phase 3 LUMEOS trial of bota-vec for XLRP enrollment target surpassed; BLA submission expected in 2024.
- Consent and Amendment allows MeiraGTx to request $25M additional notes at its discretion (previously Perceptive's).
- Shannon manufacturing facility received first commercial MIA authorization for gene therapy QC testing in Ireland.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837023014412/0001558370-23-014412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837023014412/mgtx-20230810x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-014412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer